Exelixis, Inc. EXEL was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend …
One such stock that you may want to consider dropping is Exelixis, Inc. (EXEL - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current …
The Globe and Mail now publishes quarterly reports on the performance of the …
Exelixis Inc. (EXEL) reported fourth quarter EPS of $0.12 after the close Monday, compared to $0.12 in the previous year. The result was in line with analysts' expectations. The stock is now down 2.34 on 32K shares. Exelixis was range …
This means EXEL has more control over its partnership with Roche and could become a core partner if the new studies work out, which would be big for Exelixis stock. EXEL is also working with Genentech to explore new potential uses …
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Exelixis' European partner, Ipsen, obtains positive opinion from the CHMP for the use of Cabometyx in the first …
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, …